Accessibility Menu
 
Arcturus Therapeutics logo

Arcturus Therapeutics

(NASDAQ) ARCT

Current Price$6.75
Market Cap$192.14M
Since IPO (2017)-29%
5 Year-83%
1 Year-44%
1 Month-19%

Arcturus Therapeutics Financials at a Glance

Market Cap

$192.14M

Revenue (TTM)

$74.12M

Net Income (TTM)

$65.78M

EPS (TTM)

$-2.39

P/E Ratio

-2.83

Dividend

$0.00

Beta (Volatility)

1.97 (High)

Price

$6.75

Volume

636,178.139

Open

$7.08

Previous Close

$6.76

Daily Range

$6.58 - $7.21

52-Week Range

$5.85 - $24.17

ARCT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arcturus Therapeutics

Industry

Biotechnology

Employees

111

CEO

Joseph E. Payne

Headquarters

San Diego, CA 92121, US

ARCT Financials

Key Financial Metrics (TTM)

Gross Margin

95%

Operating Margin

-1%

Net Income Margin

-89%

Return on Equity

-29%

Return on Capital

-32%

Return on Assets

-24%

Earnings Yield

-35.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$192.14M

Shares Outstanding

28.42M

Volume

636.18K

Short Interest

0.00%

Avg. Volume

495.84K

Financials (TTM)

Gross Profit

$64.20M

Operating Income

$74.95M

EBITDA

$71.93M

Operating Cash Flow

$74.27M

Capital Expenditure

$230.00K

Free Cash Flow

$74.27M

Cash & ST Invst.

$230.91M

Total Debt

$25.00M

Arcturus Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$3.08M

-85.3%

Gross Profit

$2.40M

-88.6%

Gross Margin

77.86%

N/A

Market Cap

$192.14M

N/A

Market Cap/Employee

$1.10M

N/A

Employees

174

N/A

Net Income

$29.08M

+3.1%

EBITDA

$32.16M

-10.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$205.91M

-1.2%

Accounts Receivable

$5.56M

+40.0%

Inventory

$0.00

N/A

Long Term Debt

$20.78M

-16.9%

Short Term Debt

$4.21M

+18.6%

Return on Assets

-24.26%

N/A

Return on Invested Capital

-31.93%

N/A

Free Cash Flow

$16.36M

-5662.2%

Operating Cash Flow

$16.23M

-5613.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMRXImmuneering Corporation
$4.96-4.98%
SGMTSagimet Biosciences Inc.
$4.89-4.31%
VYGRVoyager Therapeutics, Inc.
$3.96-4.12%
ACHVAchieve Life Sciences, Inc.
$2.65-8.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$167.52-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%

Questions About ARCT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.